Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Non-Current Assets (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Non-Current Assets for 16 consecutive years, with $209.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 7.84% year-over-year to $209.9 million, compared with a TTM value of $845.4 million through Dec 2025, down 10.4%, and an annual FY2025 reading of $209.9 million, down 7.84% over the prior year.
  • Non-Current Assets was $209.9 million for Q4 2025 at Catalyst Pharmaceuticals, up from $199.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $250.8 million in Q4 2023 and bottomed at -$192.8 million in Q3 2021.
  • Average Non-Current Assets over 5 years is $132.0 million, with a median of $209.9 million recorded in 2025.
  • Peak annual rise in Non-Current Assets hit 13129.86% in 2021, while the deepest fall reached 17355.99% in 2021.
  • Year by year, Non-Current Assets stood at $27.7 million in 2021, then soared by 98.05% to $54.8 million in 2022, then soared by 357.44% to $250.8 million in 2023, then fell by 9.16% to $227.8 million in 2024, then decreased by 7.84% to $209.9 million in 2025.
  • Business Quant data shows Non-Current Assets for CPRX at $209.9 million in Q4 2025, $199.1 million in Q3 2025, and $213.2 million in Q2 2025.